Tracy L Rose1, Allison M Deal2, Matthew E Nielsen3, Angela B Smith3, Matthew I Milowsky1. 1. Division of Hematology/Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. 2. Biostatistics and Clinical Data Management Core, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. 3. Urologic Oncology Program, Department of Urology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Women with advanced bladder cancer have inferior survival compared with men. However, women treated on clinical trials do not appear to have a survival disadvantage. Less frequent administration of systemic chemotherapy in women with advanced bladder cancer may contribute to their inferior survival. METHODS: The authors identified patients diagnosed with stage IV bladder cancer from 1998 through 2010 using the National Cancer Data Base, a national outcomes database that includes 70% of all newly diagnosed cancer cases in the United States. Sex differences in demographics, systemic chemotherapy administration, and overall survival (OS) were compared. RESULTS: A total of 23,981 patients were identified (35% of whom were female). Compared with men, women were older, more likely to be black, and less likely to be insured (P<.01 for all). The Charlson-Deyo comorbidity score did not differ between men and women. Women were less likely to receive systemic chemotherapy than men (45% vs 52%; adjusted relative risk, 0.91 [95% confidence interval (95% CI), 0.88-0.94]). Women had a lower median OS compared with men (8.0 months [95% CI, 7.7-8.3 months] vs 9.8 months [95% CI, 9.5-10.0 months]; P<.001). OS remained lower for women on multivariable analysis, even after adjusting for the administration of systemic chemotherapy (hazard ratio for death, 1.11 [95% CI, 1.08-1.15]). CONCLUSIONS: Women are less likely than men to receive systemic chemotherapy for advanced bladder cancer and this difference may partially account for the poorer OS observed in women. However, OS remains lower in women independent of chemotherapy use, and may be related to unmeasured comorbidities, functional status, or tumor biology. Cancer 2016;122:2012-20.
BACKGROUND:Women with advanced bladder cancer have inferior survival compared with men. However, women treated on clinical trials do not appear to have a survival disadvantage. Less frequent administration of systemic chemotherapy in women with advanced bladder cancer may contribute to their inferior survival. METHODS: The authors identified patients diagnosed with stage IV bladder cancer from 1998 through 2010 using the National Cancer Data Base, a national outcomes database that includes 70% of all newly diagnosed cancer cases in the United States. Sex differences in demographics, systemic chemotherapy administration, and overall survival (OS) were compared. RESULTS: A total of 23,981 patients were identified (35% of whom were female). Compared with men, women were older, more likely to be black, and less likely to be insured (P<.01 for all). The Charlson-Deyo comorbidity score did not differ between men and women. Women were less likely to receive systemic chemotherapy than men (45% vs 52%; adjusted relative risk, 0.91 [95% confidence interval (95% CI), 0.88-0.94]). Women had a lower median OS compared with men (8.0 months [95% CI, 7.7-8.3 months] vs 9.8 months [95% CI, 9.5-10.0 months]; P<.001). OS remained lower for women on multivariable analysis, even after adjusting for the administration of systemic chemotherapy (hazard ratio for death, 1.11 [95% CI, 1.08-1.15]). CONCLUSIONS:Women are less likely than men to receive systemic chemotherapy for advanced bladder cancer and this difference may partially account for the poorer OS observed in women. However, OS remains lower in women independent of chemotherapy use, and may be related to unmeasured comorbidities, functional status, or tumor biology. Cancer 2016;122:2012-20.
Authors: Andrea B Apolo; Vanessa Hoffman; Matthew G Kaag; David M Latini; Cheryl T Lee; Jonathan E Rosenberg; Margaret Knowles; Dan Theodorescu; Bogdan A Czerniak; Jason A Efstathiou; Matthew L Albert; Srikala S Sridhar; Vitaly Margulis; Surena F Matin; Matthew D Galsky; Donna Hansel; Ashish M Kamat; Thomas W Flaig; Angela B Smith; Edward Messing; Diane Zipursky Quale; Yair Lotan Journal: Urol Oncol Date: 2014-07-25 Impact factor: 3.498
Authors: Salim S Virani; LeChauncy D Woodard; David J Ramsey; Tracy H Urech; Julia M Akeroyd; Tina Shah; Anita Deswal; Biykem Bozkurt; Christie M Ballantyne; Laura A Petersen Journal: Am J Cardiol Date: 2014-10-12 Impact factor: 2.778
Authors: Raffaele Bugiardini; Andrew T Yan; Raymond T Yan; David Fitchett; Anatoly Langer; Olivia Manfrini; Shaun G Goodman Journal: Eur Heart J Date: 2011-03-07 Impact factor: 29.983
Authors: Wolfgang Otto; Matthias May; Hans-Martin Fritsche; Duska Dragun; Atiqullah Aziz; Michael Gierth; Lutz Trojan; Edwin Herrmann; Rudolf Moritz; Jörg Ellinger; Derya Tilki; Alexander Buchner; Thomas Höfner; Sabine Brookman-May; Philipp Nuhn; Christian Gilfrich; Jan Roigas; Mario Zacharias; Stefan Denzinger; Markus Hohenfellner; Axel Haferkamp; Stefan C Müller; Arkadius Kocot; Hubertus Riedmiller; Wolf F Wieland; Christian G Stief; Patrick J Bastian; Maximilian Burger Journal: Gend Med Date: 2012-12
Authors: Vishruth K Reddy; Varsha Jain; Robert J Wilson Ii; Lee P Hartner; Mark Diamond; Ronnie A Sebro; Kristy L Weber; Robert G Maki; Jacob E Shabason Journal: Sarcoma Date: 2021-03-13
Authors: Derek D Kao; Rocco M Ferrandino; Deborah C Marshall; Tinaye Mutetwa; Brett Miles; Joshua M Bauml; Keith M Sigel Journal: Int J Otolaryngol Date: 2022-05-02
Authors: Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali Journal: Int J Environ Res Public Health Date: 2021-05-14 Impact factor: 3.390
Authors: David D'Andrea; Beat Foerster; Surena F Matin; Ja H Ku; Tim Muilwijk; Leonardo L Monteiro; Ross Liao; Firas G Petros; Philippe E Spiess; Trinity J Bivalacqua; Kees Hendricksen; Bas W G van Rhijn; Ahmad Shabsigh; Alberto Briganti; Steven Joniau; Wassim Kassouf; Phillip M Pierorazio; Vitaly Margulis; Andrea Necchi; Shahrokh F Shariat Journal: Eur Urol Open Sci Date: 2020-06-14
Authors: Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali Journal: Int J Environ Res Public Health Date: 2022-03-04 Impact factor: 3.390